licogliflozin   Click here for help

GtoPdb Ligand ID: 10654

Synonyms: example 62 [WO2011048112A1] | LIK-066 | LIK066
Compound class: Synthetic organic
Comment: Licogliflozin (LIK-066) is an orally bioactive inhibitor of sodium/glucose cotransporters 1 and 2 (SGLT1, SGLT2). It was developed by Novartis for the treatment of obesity, non-alcoholic steatohepatitis, and type 2 diabetes, but the program was discontinued in 2018 [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 108.61
Molecular weight 416.18
XLogP 2.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc3c(c2)OCCO3)CC)[C@@H]([C@H]([C@@H]1O)O)O
Isomeric SMILES OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc3c(c2)OCCO3)CC)[C@@H]([C@H]([C@@H]1O)O)O
InChI InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
InChI Key XFJAMQQAAMJFGB-ZQGJOIPISA-N
References
1. Bebernitz GR, Bock MG, Reddy DS, Hajare AK, Vyavahare V, Bhosale B, Kurhade SE, Salunkhe V, Shaikh NS, Bhuniya D et al.. (2011)
Glycoside derivatives and uses thereof.
Patent number: WO2011048112A1. Assignee: Novartis Ag. Priority date: 20/10/2009. Publication date: 28/04/2011.
2. de Boer RA, Núñez J, Kozlovski P, Wang Y, Proot P, Keefe D. (2020)
Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
Br J Clin Pharmacol, 86 (7): 1346-1356. [PMID:32068914]
3. Li T, Jiang S, Ni B, Cui Q, Liu Q, Zhao H. (2019)
Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018.
Int J Mol Sci, 20 (18). DOI: 10.3390/ijms20184513 [PMID:31547243]